GEN Exclusives

More »

GEN News Highlights

More »
May 30, 2007

Canadian Organizations to Investigate ViRexx’ Vaccine Platform Technology

  • ViRexx Medical inked deals with the Canada's National Research Council National Institute for Nanotechnology (NRC-NINT) and Defence Research and Development Canada (DRDC) Suffield.

    "These research collaborations were supported through network and financial contributions from NRC-IRAP (Industrial Research Assistance Program), which provide us with the opportunity to explore multiple uses of our Chimigen Vaccine platform technology and establish its efficacy as an adaptable platform technology in nanoparticle and biodefence applications," comments Peter Smetek, interim CEO and chairman of the board of directors of ViRexx Medical.

    Researchers at NINT will investigate the physical characteristics and immunological and nanoparticle forming properties of the company’s Chimigen™ vaccine. Scientists at DRDC Suffield will continue to study the Chimigen Vaccine platform for biodefense applications.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should the CDC Director Resign?

Do you think the CDC chief should resign?